Morgan Stanley
CYT

Morgan Stanley’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Morgan Stanley’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$3.04K – 8037
2023
Q4 		$3.04K Hold
1,000
– – ﹤0.01% 6955
2023
Q3 		$2.84K Sell
1,000
-4,972
-83% -$13.7K ﹤0.01% 7048
2023
Q2 		$15.5K Sell
5,972
-119,231
-95% -$250K ﹤0.01% 6647
2023
Q1 		$228K Buy
125,203
+94,931
+314% +$154K ﹤0.01% 5657
2022
Q4 		$49.9K Sell
30,272
-39,062
-56% -$62.7K ﹤0.01% 6293
2022
Q3 		$133K Sell
69,334
-146,039
-68% -$381K ﹤0.01% 5933
2022
Q2 		$645K Buy
215,373
+56,023
+35% +$143K ﹤0.01% 5285
2022
Q1 		$600K Buy
159,350
+72,159
+83% +$411K ﹤0.01% 5298
2021
Q4 		$992K Buy
87,191
+84,002
+2,634% +$1.28M ﹤0.01% 5070
2021
Q3 		$56K Buy
3,189
+3,119
+4,456% +$58.3K ﹤0.01% 6669
2021
Q2 		$1K Buy
+70
New +$1.31K ﹤0.01% 7653

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.65B AUM 18.1% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Morgan Stanley's CYT Position: Q1 2024 in Review

Morgan Stanley sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 1,000 shares — an estimated $3.04K sold.

Morgan Stanley first reported a position in CYT in Q2 2021 and held it in 11 quarters. The position peaked at $992K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Morgan Stanley reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 1,000 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.04K.
  • Morgan Stanley first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Morgan Stanley's Cyteir Therapeutics, Inc. Common Stock position peaked at $992K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.